Effectiveness of fourth dose COVID-19 vaccine against the Omicron variant compared to no vaccination
Zeng, J.; Szanyi, J.; Blakely, T.
Show abstract
In response to enhanced immune evasion properties of the Omicron SARS-CoV-2 variant and waning COVID-19 vaccine effectiveness (VE), several jurisdictions have rolled out fourth dose vaccination programs. Using a system of logistic regression equations and VE estimates for a fourth dose relative to a third dose reported in an Israeli study, we estimated absolute vaccine effectiveness for third and fourth doses of mRNA COVID-19 vaccine (c.f. no vaccination) against Omicron, by clinical outcome. We found that a fourth dose restores or even enhances protection conferred by a third dose at the same time since vaccination.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK 96%
- Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar 95%
- Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar 95%
Similar papers in this journal
- Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection 97%
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France 95%
- Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting 94%
Similar papers in this journal
- Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024 94%
- Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022 93%
- Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial 93%
Similar papers in this journal
- Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong 95%
- Effectiveness of one dose of MVA-BN smallpox vaccine against monkeypox in England using the case-coverage method 95%
- Initial protection against Omicron in children and adolescents by BNT162b2 94%
Similar papers in this journal
- Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England 95%
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 95%
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.